{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T08:42:11Z","timestamp":1657615331681},"reference-count":19,"publisher":"Ubiquity Press, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5334\/tohm.584","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T12:50:18Z","timestamp":1611147018000},"page":"3","source":"Crossref","is-referenced-by-count":0,"title":["Huntington\u2019s Disease Community Perspectives on Desired Characteristics of Disease Modifying Therapies"],"prefix":"10.5334","volume":"11","author":[{"given":"Michele C.","family":"Gornick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Dayalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle E.","family":"Carlozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger L.","family":"Albin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darin B.","family":"Zahuranec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"issue":"1","key":"key20210120074946_B1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","article-title":"Huntington disease: pathogenesis and treatment","volume":"33","year":"2015","journal-title":"Neurol Clin"},{"issue":"11","key":"key20210120074946_B2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington\u2019s disease","volume":"23","year":"2008","journal-title":"Mov Disord"},{"key":"key20210120074946_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine Repeats in Neurodegenerative Diseases","volume":"14","year":"2019","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"key20210120074946_B4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin Lowering Strategies for Disease Modification in Huntington\u2019s Disease","volume":"101","year":"2019","journal-title":"Neuron"},{"key":"key20210120074946_B5","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"key20210120074946_B6","unstructured":"Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA). The Voice of the Patient: Huntington\u2019s Disease 2016 [Accessed on 4\/12\/2019]. Available from: https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM491603.pdf."},{"issue":"4","key":"key20210120074946_B7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JHD-160228","article-title":"Survey of the Huntington\u2019s Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs","volume":"5","year":"2016","journal-title":"J Huntingtons Dis"},{"issue":"10","key":"key20210120074946_B8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/mds.26318","article-title":"Potential trade-offs in treatment of premanifest Huntington\u2019s disease","volume":"30","year":"2015","journal-title":"Mov Disord"},{"issue":"7","key":"key20210120074946_B9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review","volume":"24","year":"2019","journal-title":"Drug Discov Today"},{"issue":"6","key":"key20210120074946_B10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0003-9993(98)90051-X","article-title":"Effective serial measurement of cognitive orientation in rehabilitation: the Orientation Log","volume":"79","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"key20210120074946_B11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00001199-200006000-00008","article-title":"Validity of the Orientation Log, relative to the Galveston Orientation and Amnesia Test","volume":"15","year":"2000","journal-title":"J Head Trauma Rehabil"},{"key":"key20210120074946_B12","year":"2001"},{"key":"key20210120074946_B13","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Patient Preference Information \u2013 Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. 2016 [Accessed on 12\/2\/2020]. Available from: https:\/\/www.fda.gov\/media\/92593\/download."},{"issue":"11","key":"key20210120074946_B14","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/1049732317711901","article-title":"Evolving Motivations: Patients\u2019 and Caregivers\u2019 Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington\u2019s Disease Care","volume":"27","year":"2017","journal-title":"Qual Health Res"},{"issue":"2","key":"key20210120074946_B15","first-page":"136","article-title":"Huntington Study Group","volume":"11","author":"Unified Huntington\u2019s Disease Rating Scale: reliability and consistency","year":"1996","journal-title":"Mov Disord"},{"issue":"8","key":"key20210120074946_B16","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1503\/cmaj.200016","article-title":"Early experience with medical assistance in dying in Ontario, Canada: a cohort study","volume":"192","year":"2020","journal-title":"CMAJ"},{"key":"key20210120074946_B17","first-page":"77","volume-title":"Qualitative research practice: a guide for social science students and researchers","year":"2003"},{"issue":"4","key":"key20210120074946_B18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10897-006-9021-z","article-title":"What do we tell the children? Contrasting the disclosure choices of two HD families regarding risk status and predictive genetic testing","volume":"15","year":"2006","journal-title":"J Genet Couns"},{"issue":"1","key":"key20210120074946_B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/fampra\/8.1.23","article-title":"Attitudes towards predictive testing in Huntington\u2019s disease--a deep interview study in Sweden","volume":"8","year":"1991","journal-title":"Fam Pract"}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"link":[{"URL":"https:\/\/doi.org\/10.5334\/tohm.584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T09:25:18Z","timestamp":1657531518000},"score":1,"resource":{"primary":{"URL":"https:\/\/tremorjournal.org\/article\/10.5334\/tohm.584\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,11]]}},"URL":"https:\/\/doi.org\/10.5334\/tohm.584","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}